Elisa Holmlund-Suila1, Minna Pekkinen2, Kaisa K Ivaska3, Sture Andersson1, Outi Mäkitie1,2,4,5, Heli Viljakainen1,2. 1. Children's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. 2. Folkhälsan Research Centre, Helsinki, Finland. 3. Department of Cell Biology and Anatomy, Institute of Biomedicine, University of Turku, Turku, Finland. 4. Department of Molecular Medicine and Surgery, and Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden. 5. Department of Clinical Genetics, Karolinska University Hospital, Stockholm, Sweden.
Abstract
OBJECTIVE: Although obesity is a risk factor for vitamin D insufficiency, its impact on vitamin D-binding protein (DBP) concentration, and thereby possibly also on free 25OHD, is less well known. Our aim was to compare total and free serum 25OHD, and DBP concentrations between obese and normal-weight young adults at baseline and their responses to cholecalciferol supplementation. DESIGN: A 12-week randomized, double-blinded clinical trial. PATIENTS: Obese subjectsN = 18 (BMI = 38, 67% men) with severe childhood-onset obesity and 24 normal-weight subjects (BMI = 23, 46% men), age between 15 and 25 years, were randomized into two groups to receive either placebo or cholecalciferol 50 μg (2000 IU) daily. MEASUREMENTS: At baseline, 6-week and 12-week blood samples and anthropometric measurements were collected; baseline body composition was assessed by dual-energy X-ray absorptiometry. RESULTS: At baseline, obese subjects had, compared with normal-weight, lower total and free serum 25OHD (49 vs 62 nmol/l, P = 0·041; 2·8 vs 4·7 pg/ml, P = 0·001), without differences in DBP concentrations (309 vs 346 μg/ml, P = 0·212). Cholecalciferol 50 μg per day increased both total and free 25OHD (ancova P < 0·001 and P = 0·021). The response of total 25OHD to supplementation was inferior in the obese compared with normal-weight subjects (P = 0·027). On the contrary, the change in free 25OHD concentration was similar in groups (P = 0·487). CONCLUSIONS:Obese young adults exhibit lower total and free 25OHD concentration, which is not directly explained by differences in DBP status. The response of free 25OHD to supplementation did not differ between obese and normal-weight subjects.
RCT Entities:
OBJECTIVE: Although obesity is a risk factor for vitamin Dinsufficiency, its impact on vitamin D-binding protein (DBP) concentration, and thereby possibly also on free 25OHD, is less well known. Our aim was to compare total and free serum 25OHD, and DBP concentrations between obese and normal-weight young adults at baseline and their responses to cholecalciferol supplementation. DESIGN: A 12-week randomized, double-blinded clinical trial. PATIENTS: Obese subjects N = 18 (BMI = 38, 67% men) with severe childhood-onset obesity and 24 normal-weight subjects (BMI = 23, 46% men), age between 15 and 25 years, were randomized into two groups to receive either placebo or cholecalciferol 50 μg (2000 IU) daily. MEASUREMENTS: At baseline, 6-week and 12-week blood samples and anthropometric measurements were collected; baseline body composition was assessed by dual-energy X-ray absorptiometry. RESULTS: At baseline, obese subjects had, compared with normal-weight, lower total and free serum 25OHD (49 vs 62 nmol/l, P = 0·041; 2·8 vs 4·7 pg/ml, P = 0·001), without differences in DBP concentrations (309 vs 346 μg/ml, P = 0·212). Cholecalciferol 50 μg per day increased both total and free 25OHD (ancova P < 0·001 and P = 0·021). The response of total 25OHD to supplementation was inferior in the obese compared with normal-weight subjects (P = 0·027). On the contrary, the change in free 25OHD concentration was similar in groups (P = 0·487). CONCLUSIONS:Obese young adults exhibit lower total and free 25OHD concentration, which is not directly explained by differences in DBP status. The response of free 25OHD to supplementation did not differ between obese and normal-weight subjects.
Authors: Lara Fonseca de Oliveira; Lucas Guimarães de Azevedo; Jerusa da Mota Santana; Luanna Pimenta Carlos de Sales; Marcos Pereira-Santos Journal: Rev Endocr Metab Disord Date: 2020-03 Impact factor: 6.514
Authors: Elisabet Einarsdottir; Minna Pekkinen; Kaarel Krjutškov; Shintaro Katayama; Juha Kere; Outi Mäkitie; Heli Viljakainen Journal: Endocr Connect Date: 2019-05-01 Impact factor: 3.335
Authors: Elisa Saarnio; Minna Pekkinen; Suvi T Itkonen; Virpi Kemi; Heini Karp; Kaisa K Ivaska; Juha Risteli; Marja-Kaisa Koivula; Merja Kärkkäinen; Outi Mäkitie; Harri Sievänen; Christel Lamberg-Allardt Journal: PLoS One Date: 2018-02-28 Impact factor: 3.240